Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
NCT06429306: Study of Dexycu in Treating Intraocular Inflammation

Completed
3
285
RoW
Dexycu, Investigational product, Placebo
Ocumension Therapeutics (Shanghai) Co., Ltd
Inflammation, Cataract
11/23
04/24
NCT05550363: A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)

Withdrawn
3
150
NA
Dexycu, Placebo/Vehicle
EyePoint Pharmaceuticals, Inc.
Cataract
09/23
09/23
NCT05550350: A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery

Not yet recruiting
3
150
NA
Dexycu, Placebo/Vehicle
EyePoint Pharmaceuticals, Inc.
Cataract
04/24
04/24

Download Options